Ariana Pelosci

A qualitative analysis identified 4 themes that could be improved upon to help with symptom management in patients with head and neck cancer.

Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.

By analyzing CT scans with artificial intelligence, the development of pancreatic ductal adenocarcinoma may be predicted years before actual diagnosis.

High rates of hematopoietic cell transplantation were observed in patients with relapsed/refractory acute myeloid leukemia who received 131-iodine conditioning in the phase 3 SIERRA trial.

Anetumab ravtansine yielded a manageable safety profile in patients with relapsed mesothelin-positive malignant pleural mesothelioma in the second-line setting, but it did not appear to be superior to vinorelbine.

The phase 3 JUPITER-08 trial assessed toripalimab plus chemotherapy, which was granted an orphan drug designation by the FDA, in patients with extensive-stage small cell lung cancer.

Findings from the phase 2 CARITUDE-2 trial which investigated ciltacabtagene autoleucel in patients with multiple myeloma indicated that a single infusion produced deep responses.

Patients with KRAS G12C-mutated colorectal cancer treated with sotorasib showed modest anti-tumor activity during a phase 2 trial.

Patients with estrogen receptor–positive HER2-mutated metastatic breast cancer experienced promising clinical activity following treatment with neratinib and fulvestrant.

Ixazomib did not appear to be an effective replacement for carfilzomib or bortezomib in combination regimens containing the 2 proteosome inhibitors in patients with relapsed/refractory multiple myeloma.

Through traditional treatment, acupuncture, acupressure, and mind-body therapy, Heather Greenlee, ND, PhD, MPH, discusses how clinicians who treat patients with breast cancer can become more aware of integrative approaches for their practices.

A real-world study found patients with relapsed/refractory multiple myeloma who were triple-class exposed had higher healthcare costs and unmet treatment needs.

Investigators of the phase 3 RATIONALE-309 trial found an improvement in progression-free survival for patients with recurrent or metastatic nasopharyngeal cancer treated with tislelizumab plus chemotherapy vs chemotherapy alone.

The phase 1/2 TakeAim Lymphoma trial examining emavusertib for patients with B-cell malignancies has received a partial clinical hold pending review by the FDA.

Patients with early stage non–small cell lung cancer and impaired pulmonary function could potentially benefit from treatment with stereotactic body radiotherapy.

Investigators reported topline findings from the phase 1/2 EPCORE NHL-1 trial assessing epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Bria-IMT has been granted fast track designation by the FDA for the treatment of metastatic breast cancer.

A phase 3 trial of patients with extensive-stage small cell lung cancer who were treated with adebrelimab plus chemotherapy compared with matched placebo met the primary end point of overall survival.

Between 2004 to 2016, investigators reported that mammography rates decreased among breast cancer survivors.

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Based on results from the EPIK-P1 trial, the FDA has granted accelerated approval to alpelisib for PIK3CA-related overgrowth spectrum.

Longer and more durable remissions were identified with the addition of CART-19 to ibrutinib for patients with chronic lymphocytic leukemia.

Investigators spoke to the disparities that are present in multiple myeloma and possible causes such as socioeconomic factors.

Based on results from a phase 1 trial, the FDA has granted fast track designation to PRGN-3006 UltraCAR-Tin relapsed/refractory acute myeloid leukemia.

A biologics license application for omburtamab was resubmitted following a refusal to file letter in 2020 for pediatric patients with central nervous system/leptomeningeal metastatic from neuroblastoma.

Pediatric patients with high allelic ratio FLT3/ITD–positive acute myeloid leukemia may benefit from treatment with sorafenib plus chemotherapy.

Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy.

Patients with human papillomavirus–associated oropharyngeal carcinoma who were given de-escalated doses of radiotherapy saw a better quality of life and favorable outcomes.

The addition of relacorilant to nab-paclitaxel has improved overall survival in patients with recurrent, platinum-resistant ovarian cancer.

Phillip S. Low, PhD, pioneered development of 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer and spoke about its recent approval.